Remove 2030 Remove Chemotherapy Remove Labelling
article thumbnail

Radiopharmaceuticals for prostate cancer to go nuclear with $6.3 bn in sales by 2030

Express Pharma

billion in sales by 2030, according to GlobalData. billion by 2030, far outshining Xofigo. Pluvicto is indicated for metastatic CRPC (mCRPC) patients previously treated with ADT and taxane chemotherapy. billion by 2030. bn in sales by 2030 appeared first on Express Pharma.

article thumbnail

The data are in – so will Gilead’s Trodelvy achieve its potential?

pharmaphorum

In the study, Trodelvy (sacituzumab govitecan) met its objective of reducing progression-free survival in patients with HR-positive, HER2-negative metastatic breast cancer who received multiple lines of prior treatment – including endocrine drugs, CDK4/6 inhibitors and two to four lines of chemotherapy. appeared first on.